Meeting The Unmet Need in Drug DeliveryPartnering

Intec Pharma is a drug development company, applying its innovative proprietary gastric retention technology to develop improved formulations of existing drugs.

The drugs that were selected to be improved had at least one of the following characteristics:

  • Low bioavailability

  • Significant side effects

  • Poor efficacy

  • Frequent dosing


News & Events

November 11, 2013
The Board of Directors approved the appointment of Mr. Zeev Weiss >
April 14, 2013
The Company hereby provides this immediate report that it was approved for a grant from The Michael J. Fox Foundation for Parkinson's Research >
October 14, 2012
The Company was informed by the United States Patent and Trademark Office (USPTO) that >
October 9, 2012
Success in Phase II clinical studies with the Accordion Pill Carbidopa Levodopa product for the treatment of Parkinson’s disease >
June 6, 2012
Completion of  the construction of the new production line for Phase III clinical trials >
November 22, 2011
Success in Phase II clinical trial with the Accordion-Zaleplon product for the treatment of sleep disorders >
July 17, 2011
Successful intermediate results of Phase IIb clinical trial with Accordion Pill-Carbidopa/Levodopa for Parkinson’s disease, second group >

February 28, 2011
Success in the first group of patients in Phase II clinical trials for the Accordion Pill Zaleplon for sleep disorders, intermediate results >
September 15, 2010
FDA approval for commencing Phase II trials in the US for the Accordion- Zaleplon for Sleep Disorders >
August 31, 2010
Success of Phase II b Clinical Trial with the Accordion-Pill-Levodopa Product, for the Treatment of Parkinson's disease Symptoms – Intermediate Results > 
March 18, 2010
Intec Pharma announced the successful completion of phase I clinical studies with its Accordion-Pill Baclofen
(AP-Baclofen) >
February 14, 2010
Huge success in the Initial Public Offering of Intec Pharma >
February 3, 2010
Intec Pharma announces successful completion of Phase IIA with its AP-CD/LD >